
GLP-1 drugs are taking much oxygen out of the biotechnology trade. However, many investors have been eyeing other areas in the sector, particularly cancer research. Novartis AG (NYSE: NVS) is up over 31% in 2025, and a novel cancer treatment could give the Swiss company a long runway for growth.